TY - JOUR
T1 - Assessment of the Fanconi Anemia Repair Pathway as a Predictor of Clinical Activity of Pembrolizumab (PEM).
AU - Aparo, Santiago
AU - Villalona-Calero, Miguel Angel
AU - Diaz, John Paul
AU - Diaz, Zuanel
AU - Duan, Wenrui
AU - Schroeder, Eric Douglas
AU - Gatcliffe, Troy Antony
AU - Alonso, Alfredo Pedro
AU - Cuitiva, Sebastian
AU - Albrecht, Federico
AU - Venkatappa, Siddhartha A.
AU - Guardiola Amado, Victor D
AU - Troner, Michael B.
AU - Garrido, Sara M.
AU - Walker, Gail
AU - Rubens, Muni
AU - De Zarraga, Fernando I.
AU - Vuong, Hao
N1 - 2555 Background: Given the activity of immune checkpoint inhibitors (ICI) in mismatch repair deficient tumors, we evaluated if homologous recombination repair deficiency associates with solid tumor response to ICI. Methods: We conducted a phase 2 trial (NCT03274661) of PEM in metastatic solid tumor patients progressing on standard of care and for whom PEM had no FDA approved indication.
PY - 2019
Y1 - 2019
UR - https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.2555
M3 - Article
VL - 37
JO - Journal of Clinical Oncology /American Society of Clinical Oncology (ASCO) Annual Meeting
JF - Journal of Clinical Oncology /American Society of Clinical Oncology (ASCO) Annual Meeting
ER -